MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

118.79 0.17

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

116.99

Max

119.98

Pagrindiniai rodikliai

By Trading Economics

Pajamos

11M

-48M

Pardavimai

29M

150M

Pelno marža

-31.973

Darbuotojai

846

EBITDA

20M

-37M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+44.25% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

678M

6B

Ankstesnė atidarymo kaina

118.62

Ankstesnė uždarymo kaina

118.79

Naujienos nuotaikos

By Acuity

50%

50%

183 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-07 16:58; UTC

Uždarbis

BMW Trims 2025 View, Citing Weaker Performance in China

2025-10-07 23:43; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025-10-07 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025-10-07 23:19; UTC

Rinkos pokalbiai

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025-10-07 22:40; UTC

Rinkos pokalbiai

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025-10-07 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 20:44; UTC

Karštos akcijos

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025-10-07 19:42; UTC

Rinkos pokalbiai

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025-10-07 19:23; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025-10-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025-10-07 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025-10-07 15:33; UTC

Rinkos pokalbiai

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025-10-07 15:25; UTC

Rinkos pokalbiai

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025-10-07 15:15; UTC

Rinkos pokalbiai

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025-10-07 15:04; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-10-07 15:04; UTC

Rinkos pokalbiai

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025-10-07 14:52; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

44.25% į viršų

12 mėnesių prognozė

Vidutinis 171.14 USD  44.25%

Aukščiausias 200 USD

Žemiausias 144 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

16

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

107.24 / 112.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

183 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat